(Q40721264)

English

Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia

scientific article published on February 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

quality of life

1 reference

based on heuristic

inferred from title

eradication of infectious diseases

1 reference

based on heuristic

inferred from title

peptic ulcer disease

1 reference

based on heuristic

inferred from title

Helicobacter pylori

object named as

Helicobacter pylori

1 reference

based on heuristic

inferred from title

author name string

Groeneveld PW

1

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Lieu TA

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Fendrick AM

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Hurley LB

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Ackerson LM

5

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Levin TR

6

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Allison JE

7

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

language of work or name

0 references

publication date

1 February 2001

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

96

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

338-347

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Costs of duodenal ulcer therapy with antibiotics.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

A new therapeutic option for the treatment of pneumonia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

The effect of assessment method and respondent population on utilities elicited for Gaucher disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Management of dyspepsia in primary care. GPs are already choosing eradication therapy over endoscopy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

The impact of gastroesophageal reflux disease on health-related quality of life.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Heterogeneity in the relationship between the time tradeoff and Short Form-36 for HIV-infected and primary care patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Constructing health state preference values from descriptive quality of life outcomes: mission impossible?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Projected cost-effectiveness of primary angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Alternative management strategies for patients with suspected peptic ulcer disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

A cost analysis of alternative treatments for duodenal ulcer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Prognostic significance of intraoperative rupture of ovarian cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

"Reappearance" of Helicobacter pylori after eradication: implications on duodenal ulcer recurrence: a prospective 6 year study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Recurrence ofHelicobacter pyloriInfection after Eradication: Incidence and Variables Influencing It

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Management of dyspepsia in primary care. Antibiotic resistance is a problem

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

How might general practitioner knowledge of patient Helicobacter pylori status change the management of dyspepsia in primary care?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03516.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2001.03516.X

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40721264&oldid=1905148595"